When Every Hour Counts: New Review Rethinks the Rush to Repair Ruptured Brain Aneurysms

When a brain aneurysm bursts, the bleeding that follows — aneurysmal subarachnoid hemorrhage, or aSAH — is one of the deadliest forms of stroke a patient can suffer. Although it accounts for only about five percent of all cerebrovascular events, it contributes up to 27 percent of stroke-related years of potential life lost, striking disproportionately at people in their fifth and sixth decades. For decades, neurosurgeons and interventional neuroradiologists have operated on a simple assumption: the faster the ruptured aneurysm is secured, the better the patient’s chances. A sweeping new systematic review published in the Journal of Neurology now suggests that this assumption, while partly true, hides a far more complicated and scientifically fascinating picture.

The review, led by Táya Figueiredo de Oliveira Fiore and colleagues, prospectively registered in PROSPERO and conducted under the PRISMA 2020 and SWiM reporting frameworks, synthesized 20 reports encompassing 11,096 participant records with confirmed aSAH. The studies, published between 2015 and 2026, spanned Asia, Europe, South America, North America and Oceania, and compared clinical outcomes across different onset-to-treatment windows ranging from less than six hours to fifteen days or more. Eighteen of the studies were retrospective cohorts and two were post hoc analyses of randomized trial data — but crucially, in none of them was treatment timing actually randomized, making every comparison observational by nature.

The team’s central question was deceptively simple: does the interval between aneurysm rupture and definitive repair — whether by microsurgical clipping or endovascular coiling — independently determine mortality, functional recovery, and complications such as rebleeding, vasospasm, delayed cerebral ischemia, hydrocephalus, and length of hospital stay? To answer it, the reviewers weighted propensity-adjusted and comprehensively adjusted multivariable analyses far more heavily than crude or descriptive comparisons, and graded the certainty of evidence using the GRADE framework. For the timing-mortality association, certainty was downgraded to very low — the lowest possible category — because of serious risk of bias, inconsistency, and imprecision.

One finding stood out with relative clarity: earlier aneurysm securement genuinely reduces pretreatment rebleeding, the catastrophic rerupture that can occur while the aneurysm remains unsecured. Studies that included untreated or markedly delayed patients showed dramatic gradients. In one cohort, rebleeding occurred in seven percent of patients treated within 24 hours, ten percent treated at 24 to 72 hours, and 38 percent treated after 72 hours — with 16 percent of untreated patients also bleeding. Another study reported rebleeding in zero percent of patients clipped within six hours versus 49.1 percent of those never repaired. These comparisons align with classic data showing that ultra-early treatment within six hours cuts rebleeding risk dramatically, and they underpin the 2023 American Heart Association/American Stroke Association Class 1 recommendation to treat as early as feasible, ideally within 24 hours of onset.

Beyond rebleeding, however, the evidence became murky. Across 19 studies reporting functional outcome, eight favored earlier treatment, four favored later treatment, four found no independent association after adjustment, and three showed non-significant trends. The most methodologically robust analyses — those adjusting for baseline clinical severity measured on the WFNS and Hunt-Hess scales — were predominantly null. Significant adjusted associations favoring early repair tended to arise in studies plagued by treated-survivor selection, incomplete confounder control, or composite exposure definitions. Mortality data were similarly discordant: two analyses favored earlier treatment, three favored later treatment, and four found no difference at all.

The most provocative results came from the only two studies that modeled onset-to-treatment time as a continuous variable rather than forcing patients into arbitrary cutoffs like under or over 24 hours. Using flexible cubic spline models, one large multicenter analysis of 3,560 patients identified a statistically significant U-shaped relationship between treatment time and mortality, with the estimated risk lowest at approximately 32.6 hours. The other study found a similar but non-significant pattern with a nadir near 12.2 hours. These nonlinear curves may help reconcile the seemingly contradictory findings of decades of dichotomous timing studies — but the reviewers are emphatic that they are hypothesis-generating only, not a validated therapeutic window.

Why would a mid-range interval appear optimal? The answer lies in two insidious statistical traps. The first is confounding by indication: the sickest patients, those with the worst WFNS and Hunt-Hess grades, are treated most urgently, making early treatment appear spuriously harmful in unadjusted comparisons. The second is survivor bias: a patient can only appear in a delayed-treatment group if they survive long enough to reach it, making later treatment appear spuriously beneficial. Neither bias can be fully corrected in retrospective analyses, no matter how sophisticated the propensity matching. Strikingly, in one trial analysis, the apparent excess risk of ultra-early treatment attenuated almost entirely once patients who rebled early were reclassified or excluded.

The review also examined whether the choice of repair technique modifies the timing effect. Of three studies that formally tested a modality-timing interaction, only one — the same large continuous-time analysis — found a significant interaction for mortality, with the U-shaped curve more pronounced in the microsurgical group and more gradual in the endovascular group. The other two found nothing, and stratified analyses showed no consistent modality-specific pattern. Direct clipping-versus-coiling comparisons across the included studies were heterogeneous and outcome-specific, with no consistent independent advantage for either technique after adjustment, echoing the broader randomized evidence that favors coiling in suitable patients but shows convergence in risk-adjusted contemporary cohorts.

For the secondary outcomes, the timing signal essentially vanished. Neither continuous-time analysis found any association between treatment time and delayed cerebral ischemia or postoperative cerebral ischemia. Hydrocephalus showed no reproducible link, with one unadjusted finding of more shunt-dependent hydrocephalus after early treatment likely reflecting the simple fact that sicker patients get treated sooner. Length of stay was underexplored and discordant. Isolated subgroup findings — such as higher infarction risk with treatment beyond 24 hours in moderate-grade patients, or increased procedural risk when operating during the vasospasm phase — were not reproduced across overall populations.

The reviewers conclude that current guidelines remain firmly supported: aneurysms should be secured as early as feasible, and nothing in the evidence justifies intentional delay or a specific alternative timing target. But they also issue a clear call to arms for the field. Future research must model treatment time as a continuous exposure using restricted cubic splines, rigorously adjust for clinical severity and age, stratify by modality with formal interaction testing, and — critically — include patients who die before treatment, whose absence from nearly every existing cohort distorts the entire evidence base. The review also cautions that its findings, generated predominantly in high-volume centers in Asia and Europe, may not translate to settings where patients arrive days after onset; cohorts in middle-income countries have reported median ictus-to-treatment intervals of four to nine days. Until prospective multicenter registries with standardized definitions deliver cleaner data, the race against the clock continues — guided by the one outcome where speed undeniably matters: stopping the aneurysm before it bleeds again.

Subject of Research: The association between onset-to-treatment time and clinical outcomes after aneurysmal subarachnoid hemorrhage

Article Title: Timing of aneurysm repair and clinical outcomes after aneurysmal subarachnoid hemorrhage: a systematic review

Article References: Fiore, T. F. D. O., Vieira, Â. M. A., Magalhães, F. D. F., de Souza, C. G., Alves Filho, C. A. F., & Barboza, T. (2026). Timing of aneurysm repair and clinical outcomes after aneurysmal subarachnoid hemorrhage: a systematic review. Journal of Neurology, 273(10), Article 582. https://doi.org/10.1007/s00415-026-14063-x

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14063-x

Keywords: aneurysmal subarachnoid hemorrhage, aneurysm repair timing, rebleeding, microsurgical clipping, endovascular coiling, mortality, functional outcome, confounding by indication, survivor bias, delayed cerebral ischemia, systematic review, neurocritical care